Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • Accepted Manuscript br A year period analysis of other

    2019-09-16

    Accepted Manuscript
    A 25-year Cefepime analysis of other-cause mortality in localized prostate cancer
    Sophie Knipper, Angela Pecoraro, Carlotta Palumbo, Giuseppe Rosiello, Stefano Luzzago, Zhe Tian, Alberto Briganti, Fred Saad, Derya Tilki, Markus Graefen, Pierre I. Karakiewicz
    To appear in: Clinical Genitourinary Cancer
    Please cite this article as: Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI, A 25-year period analysis of other-cause mortality
    This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    ACCEPTED MANUSCRIPT
    1 A 25-year period analysis of other-cause mortality in localized prostate cancer
    5 I. Karakiewicz2
    7 1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg,
    8 Germany
    9 2Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal
    10 Health Center, Montreal, Quebec, Canada
    11 3Department Cefepime of Urology, San Luigi Gonzaga Hospital, University of Turin, Turin, Italy
    12 4Urology Unit, ASST Spedali Civili of Brescia, Department of Medical and Surgical
    13 Specialties, Radiological Science and Public Health, University of Brescia, Brescia, Italy
    14 5Department of Urology and Division of Experimental Oncology, URI, Urological Research
    15 Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
    16 6European Institute of Oncology, Milan, Italy
    17 7Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
    19 Corresponding author: Sophie Knipper, MD
    20 Martini-Klinik Prostate Cancer Center
    21 University Hospital Hamburg-Eppendorf
    ACCEPTED MANUSCRIPT
    25 Conflict of interest
    26 The authors declare that they have no conflict of interest.
    28 MicroAbstract
    29 Other-cause mortality should have decreased over time in prostate cancer patients as patient
    30 selection for diagnosis and treatment may have improved. We tested this hypothesis in
    31 367,884 prostate cancer patients treated with radical prostatectomy or radiotherapy within the
    32 Surveillance, Epidemiology and End Results database and observed important other-cause
    33 mortality reduction over the last 25 years.
    ACCEPTED MANUSCRIPT
    35 Abstract
    36 Background: We examined the changes over time in other-cause mortality (OCM) rates in
    37 patients with clinically localized prostate cancer (PCa) as an indicator of patient selection.
    41 multivariable Cox regression analyses assessed OCM at 5 years using stratification according
    43 age group and ethnicity.
    44 Results: In RP patients, OCM rates at 5 years of follow-up decreased over time from 7.9 to
    46 greatest decrease in 5-year OCM rates over time was recorded in patients ≥75 years (16.0-
    51 corroborated in multivariable Cox regression models.
    52 Conclusions: OCM rates were highest in oldest individuals and in African-American men. In
    53 both groups, an important 5-year OCM reduction over the 25-year study span was recorded.
    54 Nonetheless, these two patient groups may still represent the ideal target for better patient
    55 selection based on OCM considerations, since their most recent OCM rates exceeded those of
    56 respectively younger and Caucasian patients.
    58 Keywords: survival, radical prostatectomy, external beam radiation therapy, SEER, life